Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Angelini Ventures has already invested €125 million in 22 startups
Presbyopia, the age-related loss of near vision, could soon be treated successfully
The audit was completed with zero critical and zero major observations
Subscribe To Our Newsletter & Stay Updated